JP2016539138A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539138A5
JP2016539138A5 JP2016536145A JP2016536145A JP2016539138A5 JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5 JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016539138 A5 JP2016539138 A5 JP 2016539138A5
Authority
JP
Japan
Prior art keywords
optionally substituted
benzo
cyclohepta
pyridazin
triazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016536145A
Other languages
English (en)
Japanese (ja)
Other versions
JP6992960B2 (ja
JP2016539138A (ja
Filing date
Publication date
Priority claimed from GB201321227A external-priority patent/GB201321227D0/en
Priority claimed from GB201323021A external-priority patent/GB201323021D0/en
Application filed filed Critical
Priority claimed from PCT/GB2014/053548 external-priority patent/WO2015082887A2/en
Publication of JP2016539138A publication Critical patent/JP2016539138A/ja
Publication of JP2016539138A5 publication Critical patent/JP2016539138A5/ja
Application granted granted Critical
Publication of JP6992960B2 publication Critical patent/JP6992960B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016536145A 2013-12-02 2014-11-28 キナーゼ阻害剤の用途 Expired - Fee Related JP6992960B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1321227.9 2013-12-02
GB201321227A GB201321227D0 (en) 2013-12-02 2013-12-02 Use of kinase inhibitors
GB1323021.4 2013-12-24
GB201323021A GB201323021D0 (en) 2013-12-24 2013-12-24 Use of kinase inhibitors
PCT/GB2014/053548 WO2015082887A2 (en) 2013-12-02 2014-11-28 Use of kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080908A Division JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Publications (3)

Publication Number Publication Date
JP2016539138A JP2016539138A (ja) 2016-12-15
JP2016539138A5 true JP2016539138A5 (enExample) 2017-12-28
JP6992960B2 JP6992960B2 (ja) 2022-02-03

Family

ID=52016110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536145A Expired - Fee Related JP6992960B2 (ja) 2013-12-02 2014-11-28 キナーゼ阻害剤の用途
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Country Status (4)

Country Link
US (1) US9801880B2 (enExample)
EP (1) EP3076966A2 (enExample)
JP (2) JP6992960B2 (enExample)
WO (1) WO2015082887A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
ES2857081T3 (es) 2015-07-16 2021-09-28 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN115504967A (zh) * 2021-06-23 2022-12-23 南京正大天晴制药有限公司 作为axl抑制剂的1,2,4-三唑化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483400A4 (en) * 2002-02-12 2007-07-11 Quark Biotech Inc USE OF THE AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF A KIDNEY DISEASE
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
PL1686997T3 (pl) * 2003-11-18 2009-09-30 Novartis Ag Inhibitory zmutowanej formy KIT
PL2078010T3 (pl) * 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
KR100900289B1 (ko) 2007-06-21 2009-05-29 엘지전자 주식회사 직교 주파수 분할 다중화 시스템에서 제어 채널을 송수신하는 방법
WO2009054939A2 (en) * 2007-10-19 2009-04-30 Cell Signaling Technology, Inc. Cancer classification and methods of use
JP5908728B2 (ja) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
US8546433B2 (en) * 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8603740B2 (en) * 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012143143A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2016539138A5 (enExample)
JP2020105211A5 (enExample)
JP5529004B2 (ja) Hsp90阻害剤として有用なトリアジノンおよびジアジノン誘導体
JP5441691B2 (ja) Hsp90活性を調節するトリアゾール化合物
JP7014731B2 (ja) 置換アミノプリン化合物、その組成物、及びそれらを用いた治療方法
CN105492439B (zh) 作为溴结构域抑制剂的取代的双环化合物
AU2014272776C1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
JP6078639B2 (ja) Abl1、abl2およびbcr−abl1の活性を阻害するためのベンズアミド誘導体
JP2012515225A5 (enExample)
TW201408298A (zh) 免疫相關及發炎疾病之治療
JP2016517857A5 (enExample)
JP2017511360A5 (enExample)
JP2015515469A (ja) Hsp90阻害剤としてのトリアゾール誘導体
WO2015082887A2 (en) Use of kinase inhibitors
AU2018335617B2 (en) Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
JP2018516963A (ja) RORγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
JP2016525104A5 (enExample)
Mounika et al. An overview of CDK enzyme inhibitors in cancer therapy
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
JP2015515477A (ja) Hsp90活性を調節する新規トリアゾール化合物
WO2024067631A1 (zh) Fak抑制剂及诱导免疫原性细胞死亡的物质的药物组合及用途
AR044648A1 (es) Combinaciones terapeuticas
TW202131917A (zh) 併用醫藥
CA3212085A1 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
WO2018213712A1 (en) Pyrazoloquinazolinone antitumor agents